Inspired by Patients
At Agios, patients inspire us and are central to everything we do. Our unique and intense focus on boundary-breaking science will enable us to uncover therapeutics with the potential to change both patients’ lives and the cancer treatment paradigm. We believe these therapeutics will provide important new options for oncologists and patients that could be superior or complementary to existing therapies.
On November 17, 2011, Agios CEO David Schenkein, M.D., was honored with the Corporate Vision Award by Gilda's Club NYC at its 16th Annual Benefit Gala. The goal of the event is to raise awareness and funds to provide social and emotional support for cancer patients and their families.
Dr. Schenkein during his speech at the Gilda's Club NYC Annual Benefit Gala
Barry Greene, President and Chief Operating Officer of Alnylam Pharmaceuticals; Julian Adams, Ph.D., President, Research and Development at Infinity Pharmaceuticals; Dr. Schenkein
Kevin Starr, Partner at Third Rock Ventures and former Agios Interim CEO; Craig Thompson, Agios co-founder and the President and CEO, Memorial Sloan Kettering Cancer Center; Duncan Higgons, Chief Operating Officer at Agios; and Dr. Schenkein